【摘 要】
：
The targeted therapies in breast cancer have pre-ceded the term "targeted" since they existed for many years targeting hormonal receptors, later Her2 pathways and established an important role in the
【机 构】
：
Clinical Trials Office New York University Cancer Institute New York University School of Medicine U
【出 处】
：
(BITs 3rd Annual World Cancer Congress-2010, Breast Cancer C
论文部分内容阅读
The targeted therapies in breast cancer have pre-ceded the term "targeted" since they existed for many years targeting hormonal receptors, later Her2 pathways and established an important role in the management of both metastatic and adjuvant breast cancer.Novel agents that target specific pathways (EGFR, VEGF, RAF, m-TOR etc) have not demonstrated significant activity as single agents in the presence of metastatic disease.Pre-clinical evidence suggested multiple areas of "cross-talk" between different pathways that in-vitro predicted enhanced efficacy, and possibly "overcoming" resistance in combination with "traditional" therapies: chemotherapy, hormonal therapy and anti-Her 2 agents.Many trials conducted as single arm, or randomized Phase 2 design with angiogenesis oral tyrosine kinase inhibitors failed to establish significant additional benefit in combinations with hormonal therapy agents.The combinations of antibody based regimens (Transtuzumab, and Bevacuzimab) with hormonal therapy are being investigated in current clinical trials.The combinations of Bevacuzimab with different chemotherapy agents in the metastatic agents have been studies in large randomized Phase Ⅲ trials and have been recently released.The ongoing large adjuvant trials introduce the targeted agents in the adjuvant scenario can establish a very important role of these agents in the "preventive" role, possibly affecting the tumor micro-environment and stem cells.Novel approaches in study design, as well as clinical scenarios are needed to investigate the targeted agents and their combinations.
其他文献
A community based study was conducted during 2008-09 amongst women employees from various offices of Delhi.A total of 424 women who volunteered to participate in the study were trained in the techniqu
Background: Systematic reviews have found that LH-RH agonists are effective in the treatment of premenopausal women with early breast cancer.In an extended phase Ⅱ study, 180 premenopausal women with
Background: PDGF-C has been described in tumor associated fibroblasts, yet little is known about its expression in human breast cancer.Methods: We have generated and characterized a monoclonal antibod
Cellular signalling plays a central role in cancer biology.Many oncogenes and tumor suppressor target the functions of signalling networks underlying cancer malignant phenotype.The reverse phase prote
HER2 (human epidermal growth factor receptor 2) is an important biomarker whose status plays a pivotal role in therapeutic decision making for patients with breast cancer and in determining their clin
The identification of mechanisms that regulate proliferation and survival of tumor cells is leading to the development of novel therapeutic approaches.To date, several agents specific for molecular ta
The optimal sequencing of chemotherapy and radiotherapy after breast surgery was largely studied but remains controversial.Concurrent chemo-radiotherapy is a valuable method for adjuvant treatment of
Multiple studies have shown the limitations of single modality imaging with interobserver differences in lumpectomy cavity definition.We compared contouring of lumpectomy cavity volume, extent, and ca
Purpose: to compare the surgery and radiotherapy related outcomes, toxicities and cosmesis of patients undergoing breast conserving surgery and adjuvant external beam radiotherapy having intraoperativ
Taxanes (paclitaxel and docetaxel) are mitotic inhibitors and antimicrotubule agents that are highly active in the treatment of breast cancer.Both taxanes require solvents, Cremphor EL and polysorbate